
[Thomas Krol](#), BS, PharmD, CLP, RPH has more than 30 years' experience in biopharma research and development (R&D), innovation, marketing, and business development. Tom's passion is to deliver the promise of new scientific discoveries to people who can benefit from them. He has been starting and managing life science start-ups throughout the United States for over 20 years.

Tom currently serves in Executive Management at Novadiol, Axolo Pharma, and KrolPharma Resources. Prior to these roles he was Managing Director of Human Health Investments for the Kansas Bioscience Authority (KBA), a \$583 million fund. Dr Krol's roles have varied over time, from R&D and clinical research roles at Burroughs Wellcome (now GSK) to international commercialization of products at Marion Labs (now Sanofi) and Searle (now Pfizer). Tom has also been active in Licensing of products and technologies for smaller companies like CyDex (now Ligand), Oakwood Labs, and Novadiol, and has lead negotiations of dozens of license deals valued more than \$200 million.

Working for both biotech startups and big pharma, Tom has directly contributed to the successful development and commercialization of more than 20 biopharma products including celecoxib (Celebrex®), injectable ziprasidone (Geodon®), vigabatrin (Sabril®), fexofenadine (Allegra®), diltiazem (Cardizem®), and doxacurium (Nuromax). His experience has spanned many therapeutic areas including allergy/immunology, rheumatology, nephrology, ophthalmology, dermatology, infectious disease, neurology, anesthesia/analgesia/pain, cardiology, psychiatry, pulmonology, orphan, and rare diseases. He has served on many Boards of Directors and continues this role for several startups. Tom holds a B.S. in Pharmacy from Ferris State University; a Pharmacy Doctorate from the University of Utah, completed his residency at the University of Utah Hospitals, and a post-doctoral fellowship at the University of North Carolina.